• Consolidated turnover of €100.2 million, +14.0% at constant rates
• Increase in EBITDA to €26.1 million (+18.7%), EBITDA rate of 26.1%
• Profitable current operating result of €10.3 million
• Cash position of €37.2 million as of June 30, 2023
Valence, October 18, 2023, 6:00 p.m. CEST – Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, PEA-PME eligible), a leading French player in the market for surgical technologies intended for orthopedics for the lower limbs, announces its annual results 2022-23.
Olivier Jallabert, Managing Director of Amplitude Surgical, declares: “The Group’s turnover for the 2022-23 financial year shows an increase of +14.0% at constant rates compared to the previous financial year. The activity is progressing in particular thanks to revenue growth of +15.8% in France, benefiting from favorable commercial dynamics. The increase in activity combined with control of operational costs led to an increase in EBITDA of +18.7% to €26.1 million. Current operating profit increased to €10.3 million. The sale of the Novastep activities made it possible to reduce the Group’s debt and strengthen its financial structure, which will allow it to continue the dynamic of commercial development and investment in technological projects. »